NASDAQ:PCRX - Pacira Biosciences Stock Price, Forecast & News

Pacira Biosciences trades on the NASDAQ under the ticker symbol "PCRX."

Pacira Biosciences Inc (NASDAQ:PCRX) issued its quarterly earnings results on Thursday, November, 7th. The company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.35. The firm earned $104.69 million during the quarter, compared to the consensus estimate of $104.88 million. Pacira Biosciences had a return on equity of 10.19% and a net margin of 0.55%. The company's revenue was up 25.5% on a year-over-year basis. During the same period last year, the company earned $0.31 earnings per share. View Pacira Biosciences' Earnings History.

Pacira Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Pacira Biosciences.

Pacira Biosciences will be holding an earnings conference call on Thursday, February 20th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Pacira Biosciences updated its FY 2019 Pre-Market earnings guidance on Thursday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $421-421 million, compared to the consensus revenue estimate of $418.06 million.

12 equities research analysts have issued 12 month target prices for Pacira Biosciences' shares. Their forecasts range from $38.00 to $85.00. On average, they expect Pacira Biosciences' stock price to reach $53.73 in the next twelve months. This suggests a possible upside of 7.5% from the stock's current price. View Analyst Price Targets for Pacira Biosciences.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira Biosciences in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pacira Biosciences.

Headlines about PCRX stock have trended somewhat positive recently, according to InfoTrie. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pacira Biosciences earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Pacira Biosciences.

Pacira Biosciences saw a increase in short interest in January. As of January 31st, there was short interest totalling 4,160,000 shares, an increase of 10.9% from the January 15th total of 3,750,000 shares. Based on an average daily trading volume, of 479,300 shares, the days-to-cover ratio is presently 8.7 days. Currently, 10.3% of the shares of the company are sold short. View Pacira Biosciences' Current Options Chain.

Some companies that are related to Pacira Biosciences include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Allergan (AGN), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT) and Endo International (ENDP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira Biosciences investors own include Gilead Sciences (GILD), Celgene (CELG), ACADIA Pharmaceuticals (ACAD), Clovis Oncology (CLVS), Incyte (INCY), Micron Technology (MU), Bausch Health Companies (BHC), Exelixis (EXEL), Neurocrine Biosciences (NBIX) and Netflix (NFLX).

Pacira Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (4.31%), Baillie Gifford & Co. (3.32%), State Street Corp (3.19%), Schroder Investment Management Group (2.18%), Spyglass Capital Management LLC (2.05%) and Tamarack Advisers LP (1.49%). Company insiders that own Pacira Biosciences stock include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, Gary W Pace, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Paul J Hastings and Richard Scranton. View Institutional Ownership Trends for Pacira Biosciences.

PCRX stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Point72 Asset Management L.P., Marshall Wace LLP, Tamarack Advisers LP, AQR Capital Management LLC, Maverick Capital Ltd., First Trust Advisors LP and PNC Financial Services Group Inc.. Company insiders that have sold Pacira Biosciences company stock in the last year include Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Paul J Hastings and Richard Scranton. View Insider Buying and Selling for Pacira Biosciences.

PCRX stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Spyglass Capital Management LLC, Baillie Gifford & Co., Great Lakes Advisors LLC, Schroder Investment Management Group, California Public Employees Retirement System, UBS Group AG and Great West Life Assurance Co. Can. Company insiders that have bought Pacira Biosciences stock in the last two years include Gary W Pace and Mark A Kronenfeld. View Insider Buying and Selling for Pacira Biosciences.

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PCRX stock can currently be purchased for approximately $49.99.

Pacira Biosciences has a market capitalization of $2.09 billion and generates $337.28 million in revenue each year. The company earns $-470,000.00 in net income (profit) each year or $0.29 on an earnings per share basis. Pacira Biosciences employs 518 workers across the globe.View Additional Information About Pacira Biosciences.

The official website for Pacira Biosciences is http://www.pacira.com/.

Pacira Biosciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]